Pfizer’s Magic Drug for Weight Loss 💊

Pfizer’s Magic Drug for Weight Loss

Pfizer’s oral drug, Danuglipron, has shown promising results in phase two clinical trials, demonstrating comparable weight loss to Novo Nordisk’s blockbuster injection, Ozempic, but with a quicker onset of action. The findings, presented at a medical conference and now released in a peer-reviewed study by JAMA Network, highlight the potential of Danuglipron as an effective treatment for weight loss in patients with Type 2 diabetes. In the trial, 411 adults with Type 2 diabetes were administered Danuglipron twice a day or a placebo. Those who received the 120-milligram dosage of Danuglipron lost an average of 10 pounds over 16 weeks, like the weight loss observed in phase three clinical trial of Ozempic, where participants using the 1-milligram injection lost around 9.9 pounds over 30 weeks with weekly administration. The results indicate that Danuglipron could offer comparable weight loss benefits to Ozempic in a shorter duration. Additionally, Pfizer’s oral formulation provides an advantage over Ozempic’s frequent injections, offering a more convenient treatment option. Both Danuglipron and Ozempic belong to the class of drugs known as glucagon-like peptide-1 antagonists, which mimic the action of the gut hormone GLP-1. These drugs not only help in weight management but also aid in managing Type 2 diabetes by stimulating insulin release from the pancreas and lowering blood sugar levels.

The entrance of Pfizer into the weight loss drug market, following the success of Novo Nordisk’s Ozempic and Wegovy, has attracted attention. These medications have gained popularity, with celebrities, social media influencers, and even Elon Musk reportedly using them for weight management. However, concerns have been raised about perpetuating a harmful diet culture emphasizing weight loss and thinness. Some patients discontinuing these drugs have also experienced difficulty controlling weight rebound. The implications for the stock of these companies could be significant. Positive clinical trial results for Pfizer’s Danuglipron may generate investor interest and boost Pfizer’s stock. On the other hand, Novo Nordisk’s market position in the weight loss drug segment could face increased competition, which might impact the company’s stock performance.

What do you think about the drugs? Will they see gaining popularity?

Want to learn how to invest? Download the Invstr app, where you can play Fantasy Finance and manage a virtual investment portfolio or open a brokerage account and invest for real. Take our interactive investing course on Invstr Academy and become a better investor today!

I am not a financial advisor and my comments should never be taken as financial advice. Investments come with risk, so always do your research and analysis beforehand.

Share:

More Posts

Get your daily Invstr Crunch

Get the market news and updates you need, delivered to your inbox or available on our daily podcast.

Risk Disclosure:

Invstr is not a bank and banking services are provided by Vast Bank, N.A.

Brokerage and Banking services are currently only available to U.S. residents.

Invstr app and web services are provided by Invstr Ltd. Advisory services are provided by Invstr Financial LLC, an investment adviser registered with the Securities Exchange Commission (SEC) details of which can be obtained here. Securities brokerage and custody services are provided by Apex Clearing, a broker dealer registered with the SEC and a member of FINRA and SIPC. There is no bank guarantee on securities and securities may lose value.

Investing involves risk and can lead to losses. Past performance does not guarantee future results.

Invstr app and web services are provided by Invstr Ltd. Invstr+ advisory services are provided by Invstr Financial LLC, an investment adviser registered with the Securities Exchange Commission (SEC). Securities brokerage and custody services are provided by Apex Clearing, a broker dealer registered with the SEC and a member of FINRA and SIPC. There is no bank guarantee on securities and securities may lose value. Vast Bank N.A. a nationally chartered bank and member of the FDIC, provides the banking products, including the products and services related to digital asset accounts. As with any asset, the value of Digital assets can go up or down and there can be a substantial risk that you lose money buying or holding digital assets. You should carefully consider whether trading or holding Digital assets is suitable for you in light of your financial condition. Your digital account does not support wallet to wallet transferring of your digital assets (i.e. cryptocurrencies) outside the platform. Any Digital Assets in your digital asset account are not insured by any government entities, including but not limited to FDIC or SIPC. The Invstr Visa® Debit Card is issued by Vast Bank, N.A. pursuant to a license from Visa U.S.A Inc and may be used everywhere Visa debit cards are accepted. Invstr Ltd, Invstr Financial LLC and Invstr Securities Ltd are subsidiaries of Marketspringpad Holdings (collectively “Invstr”) and Invstr is solely responsible for the application services and website content.

Watchlists provided when users first access the service are not a recommendation to invest. Instead they are provided to help users better navigate the service. Users are free to edit and create their own watchlists. From time to time, Invstr will suggest instruments solely based on an individual’s interest and the interest levels of the Invstr community. The statistical and portfolio builder models generated by Invstr do not reflect actual investment results and are not guarantees of future results. Comments provided by Invstr leaders, influencers or members of the Invstr Community are not recommendations and should not be construed as such. Invstr does not endorse the content or the positions posted by them. Their investment approach, and that of the models provided by Invstr, may be different from yours and may not be appropriate for you.